Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散)

Shu Xu; Rou Ma; Xiao-mei Hu; Yong-gang Xu; Xiao-hong Yang; Hong-zhi Wang; Shu-zhen Sun; Feng Liu

doi:10.1007/s11655-011-0894-9

Your Location：

Home >

Browse articles >

Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散)

Updated：2021-08-27

- Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散)
- Chinese Journal of Integrative Medicine Vol. 17, Issue 11, Pages: 834-839(2011)
- Affiliations：
  
  Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 30973903, 30973812)
- DOI：10.1007/s11655-011-0894-9
  CLC：
- Published：2011，
  
  Published Online：6 November 2011，
Scan for full text
Xu, S., Ma, R., Hu, Xm. et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散)., Chin. J. Integr. Med. 17, 834–839 (2011). https://doi.org/10.1007/s11655-011-0894-9

Shu Xu, Rou Ma, Xiao-mei Hu, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散). [J]. Chinese Journal of Integrative Medicine 17(11):834-839(2011)
Xu, S., Ma, R., Hu, Xm. et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散)., Chin. J. Integr. Med. 17, 834–839 (2011). https://doi.org/10.1007/s11655-011-0894-9 DOI：

Shu Xu, Rou Ma, Xiao-mei Hu, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散). [J]. Chinese Journal of Integrative Medicine 17(11):834-839(2011) DOI： 10.1007/s11655-011-0894-9.

摘要

To observe the clinical effectiveness of Qinghuang Powder (青黄散

QHP) combined with Bupi Yishen Decoction (补脾益肾汤

BPYS) in treating myelodysplastic syndrome (MDS)

and its relationship with France

America

and Britain (FAB) type

international prognosis scaling system (IPSS) risk

and chromosome karyotype. There were 124 MDS patients subjected to the tests. By FAB typing

91 patients were typed as refractory anemia (RA) type and 33 as refractory anemia with excess of blasts (RAEB) type; by IPSS scale

21 were sorted to low risk

77 to moderate risk I

20 to moderate risk II

and 6 to high risk; 78 of them had normal chromosome and 46 with abnormal chromosome

including 26 of trisomy 8. All patients were treated with QHP+BPYS

and the changes of peripheral blood figure and bone marrow were observed. After treatment

the general effective rate was 72.58% (90/124)

which in the patients of RA type was 80.22% (73/91) and in RAEB type 51.52% (17/33). The former was better than that in the later (P<0.01). For the analysis in the patients of different IPSS risk degrees

the effective rate was 95.24% (20/21) in the lowrisk group

72.73% (56/77) in moderate risk I

65.00% (13/20) in moderate-risk II

and 16.67% (1/6) in high-risk group. Those in the first two groups were superior to that in the latter two (P<0.01). The effective rate was 79.49% (61/78) in the patients with normal chromosome and was 60.87% (28/46) in the patients with abnormal chromosome

showing a significant difference between them. While in the patients of trisomy 8

it was 73.08% (19/26)

which was parallel to that in the patients with normal chromosome. The effectiveness of QHP+BPYS comprehensive therapy for MDS is unquestionably good

and it is markedly correlated with the FAB type and IPSS risk degree of the disease

as well as the normality of chromosome in the patient.

Abstract

To observe the clinical effectiveness of Qinghuang Powder (青黄散

QHP) combined with Bupi Yishen Decoction (补脾益肾汤

BPYS) in treating myelodysplastic syndrome (MDS)

and its relationship with France

America

and Britain (FAB) type

international prognosis scaling system (IPSS) risk

and chromosome karyotype. There were 124 MDS patients subjected to the tests. By FAB typing

91 patients were typed as refractory anemia (RA) type and 33 as refractory anemia with excess of blasts (RAEB) type; by IPSS scale

21 were sorted to low risk

77 to moderate risk I

20 to moderate risk II

and 6 to high risk; 78 of them had normal chromosome and 46 with abnormal chromosome

including 26 of trisomy 8. All patients were treated with QHP+BPYS

and the changes of peripheral blood figure and bone marrow were observed. After treatment

the general effective rate was 72.58% (90/124)

the effective rate was 95.24% (20/21) in the lowrisk group

72.73% (56/77) in moderate risk I

65.00% (13/20) in moderate-risk II

showing a significant difference between them. While in the patients of trisomy 8

it was 73.08% (19/26)

which was parallel to that in the patients with normal chromosome. The effectiveness of QHP+BPYS comprehensive therapy for MDS is unquestionably good

and it is markedly correlated with the FAB type and IPSS risk degree of the disease

as well as the normality of chromosome in the patient.

关键词

myelodysplastic syndromeQinghuang PowderrealgarBupi Yishen Decoctionclinical effectiveness

Keywords

myelodysplastic syndromeQinghuang PowderrealgarBupi Yishen Decoctionclinical effectiveness

references

Xu S, Hu XM, Xu YG. Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing Shen and strengthening Pi. Chin J Integr Tradit West Med (Chin) 2008;28:216–219.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199.

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.

Mitelman F. ISCN (1995). An international system for human cytogenetic nomenclature. Basel, Swizeland: S. Karger; 1995.

Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–3674.

William Blum. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2010:314-321.

Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.

Germing U, Gattemann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposal for a new classifications of primary myelodysplastic syndromes: a retrospective analysis of 1 600 patients. Leukemia Res 2000;25:983–993.

Haase D, Fonatsch C, Freund M, Wörmann B, Bodenstein H, Bartels H, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995;70:171–178.

Ma R, Hu XM. Treatment focused on myelodysplastic syndromes based on cytogenetic categories. J Leukemia Lymphoma (Chin) 2010;19:262–264.

Chen GQ, Zhu J, Shi X G, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic troxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052.

Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 2001;38:26.

Xu S. The clinical study of combinative treatment of Huayu Bushen method with androgen in myelodysplastic syndromes. Beijing: Doctoral Dissertation of China Academy of Chinese Medical Sciences; 2004.

Xu S, Xu YG, Yang XH, Hu XM, Wang HZ, Liu F, et al. Analysis of the quantity and function of innate immunologic cell in patients of myelodysplatic syndrome (MDS). Chin J Immun (Chin) 2009;25:596–600.

FULL TEXT LINK

More>

Views

373

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Realgar-induced apoptosis of cervical cancer cell line Siha via cytochrome c release and caspase-3 and caspase-9 activation

Some reflections on the evaluation of clinical effectiveness of Chinese medicine in China

Clinical study on the treatment of knee osteoarthritis of Shen (肾)-Sui (髓) insufficiency syndrome type by electroacupuncture

Modulation of gene expression networks underlying Realgar-Induced differentiation of acute promyelocytic leukemia cells

Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome

Related Author

No data

Related Institution

Department of Obstetrics and Gynecology, Tongji Hospital, Medical College of Wuhan University

Department of Obstetrics and Gynecology, No. Air Force Hospital

Department of Gynecology, Renmin Hospital of Wuhan University

School of Public Health and Primary Care, The Chinese University of Hong Kong

Fuzhou Municipal Hospital of Integrative Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰